[在代谢性减肥手术-添加剂药物治疗或手术转换后,治疗成功率低于最佳?]
Jakob Lauerer1, Lars Kollmann2, Ann-Cathrin Koschker3
1Klinik und Poliklinik für Allgemein‑, Viszeral‑, Transplantations‑, Gefäß- und Kinderchirurgie, Universitätsklinikum Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Deutschland. Lauerer_j@ukw.de.
Chirurgie (Heidelberg, Germany)
|September 16, 2025
概括
代谢性减肥手术 (MBS) 对病态肥胖有效,但不理想的结果需要进一步管理. 选择包括转换手术或类似于葡萄糖类1 (GLP-1) 的类似物,以改善结果.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 手术方面的创新.
背景情况:
- 致病性肥胖是一种具有重大健康影响的慢性疾病.
- 代谢性减肥手术 (MBS) 提供有效的减肥和并发症改善.
- 在MBS之后的低于最佳结果带来了临床挑战.
研究的目的:
- 定义MBS后不理想的治疗成功率.
- 审查可用的治疗选择,以管理不理想的MBS结果.
- 概述个性化患者护理的决策过程.
主要方法:
- 关于MBS后治疗策略的文献综述.
- 对转换手术风险和益处的分析.
- 对药理干预措施的评估,包括GLP-1类似物.
主要成果:
- 低于最佳的结果包括不足的减肥,体重恢复和不良的并发症控制.
- 转换手术可以改善体重轨迹,但具有更高的风险.
- GLP-1类似物显示有效性,具有有利的副作用概况.
结论:
- 个性化治疗决策对于管理低于最佳的MBS结果至关重要.
- 在跨学科框架内考虑患者的并发症和偏好是必不可少的.
- 应评估手术和药物选择,以实现个性化的患者管理.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Peptic Ulcer Disease V: Surgical Management and Nursing Care
830
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
830
Chronic Pancreatitis II: Collaborative Care
315
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
315


